جستجوی مقالات مرتبط با کلیدواژه "vegfr1" در نشریات گروه "پزشکی"

Vascular endothelial growth factor (VEGF) is one of the main angiogenesis regulators in solid cancers. The brain solid tumors are life threatening diseases in which angiogenesis is an important phase of development and progression.
In the present study the gene expression of VEGF-A and VEGF receptor (VEGF-R1) were evaluated in CNS brain tumors.

The quantification of the VEGF-A and VEGF-R1 expressions was carried out by real-time PCR on fresh biopsies of 38 supratentorial brain tumors compared to 30 non-tumoral tissues. Then the correlations were investigated with clinic-pathological and demographic factors of the patients.

PCR products sequencing confirmed the validity of the qRT-PCR. Although, VEGF-A and VEGF-R1 expression showed increased trends with progression of cell proliferation in different stages of astrocytoma (p=0.006,p=0.07, respectively), in case of VEGF-R1 did not met 95% confidence interval in other brain tumors. An increasing trend in VEGF-A and a declining trend in VEGF-R1 expression from stage-I to II were observed in meningioma.VEGF-A and VEGF-R1 expressions had not significant correlation with age and gender. Although, peritumoral brain edema (PTBE) in astrocytoma was significantly associated with tumor stages (p=0.01), VEGF-A and VEGF-R1 had not associations with PTBE in meningioma and metastasis.

VEGF-A is a valuable factor for prognosis of PTBE and malignancy stage in astrocytoma, and useful for monitoring of the treatment approaches.

Triple-negative breast cancer (TNBC) is specified by high vascularity and repetitious metastasis. Although several studies have indicated that angiogenesis has an important role in invasive breast cancer, a suitable model of TNBC that can show the exact onset of angiogenesis factors still needs to be developed. The purpose of this study is to determine the expression level of angiogenesis factors in different clinical stages of the 4T1 tumor as TNBC mouse model.

Twenty mice were injected by the 4T1 cell line, and four mice selected as healthy controls. Following by tumor induction, the mice were randomly put into four groups, each contains four mice. Once the tumor volume reached to the early stage (<100 mm3 ), intermediate stage (100-300 mm3 ), advanced stage (300-500 mm3 ), and end stage (>500 mm3 ), they were removed by surgery. Then, the expression levels of Hif1α, VEGFR1, and VEGFR2 genes, as well as tumor markers of VEGF, bFGF and CD31, were evaluated by qPCR and immunohistochemistry (IHC) respectively. The statistical analysis was done by SPSS version 16.

TNBC tumors were confirmed and multi-foci metastasis in the lung were seen. The mRNA and protein expression levels of the angiogenesis factors increased in the early stage and as the tumor grew, their expression level enhanced dramatically.

The 4T1 syngeneic mouse tumor may serve as an appropriate TNBC model for further investigation of the angiogenesis and therapies. Moreover, angiogenesis factors are induced before the advanced stage, and anti-angiogenesis therapy is necessary to be considered at the first line of treatment in TBNC.